Home › Research › Costs and economics
Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach
Xiangxiang Jiang, Gang Lv, Jordan Franklin, Minghui Li, Z Kevin Lu. BMC geriatrics, 2025-08-25
Topic: Drug trials: efficacy and safety
Plain-language summary
A total of 12,764,487 weighted older adults with ADRD were included, with 34.60% of them using anti-dementia drugs. Using anti-dementia drugs could significantly reduce Medicare costs and inpatient costs by $4,804.26 and $2,842.48 on average (P < 0.001), while did not significantly influence total costs, OOP costs, and outpatient costs. ChEIs use could help decrease Medicare costs and inpatient costs significantly (P < 0.05), whereas the NMDAR antagonist (memantine) showed no statistically significant effect across all cost types. Both donepezil and rivastigmine could help significantly decrease Medicare costs and inpatient costs (P < 0.001). Additionally, anti-dementia drug use could significantly reduce Medicare costs and inpatient costs among non-Hispanic Whites, and significantly lower inpatient costs among non-Hispanic Blacks (P < 0.05). This study revealed the causal relationship between anti-dementia drug use and Medicare costs by employing DML. ChEIs were found to be contributors to the decreased Medicare costs and inpatient costs, which could mainly be attributed to donepezil. The use of donepezil should be expanded, considering the significant benefits. Furthermore, a lower OOP cap for ADRD beneficiaries should be established under the IRA.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jiang, X., Lv, G., Franklin, J., Li, M., & Lu, Z. K. (2025). Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach. BMC geriatrics. https://doi.org/10.1186/s12877-025-06298-6
Vancouver
Jiang X, Lv G, Franklin J, Li M, Lu ZK. Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach. BMC geriatrics. 2025. doi:10.1186/s12877-025-06298-6. PMID: 40855523.
BibTeX
@article{jiang2025-40855523,
author = {Jiang, Xiangxiang and Lv, Gang and Franklin, Jordan and Li, Minghui and Lu, Z Kevin},
title = {{Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach}},
journal = {BMC geriatrics},
year = {2025},
doi = {10.1186/s12877-025-06298-6},
pmid = {40855523},
url = {https://doi.org/10.1186/s12877-025-06298-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- A total of 12,764,487 weighted older adults with ADRD were included, with 34.60% of them using anti-dementia drugs.
- Using anti-dementia drugs could significantly reduce Medicare costs and inpatient costs by $4,804.26 and $2,842.48 on average (P < 0.001), while did not significantly influence total costs, OOP costs, and outpatient costs.
- ChEIs use could help decrease Medicare costs and inpatient costs significantly (P < 0.05), whereas the NMDAR antagonist (memantine) showed no statistically significant effect across all cost types.
- Both donepezil and rivastigmine could help significantly decrease Medicare costs and inpatient costs (P < 0.001).
- Additionally, anti-dementia drug use could significantly reduce Medicare costs and inpatient costs among non-Hispanic Whites, and significantly lower inpatient costs among non-Hispanic Blacks (P < 0.05).
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Effect size34.60%
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 26 of the 56 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC geriatrics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40855523) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 26 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 26 of the 56 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Costs and economics from nearby years
Also tagged “racial”
265 studies in the library carry the topic tag “racial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 265 tagged studies.